Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States

Cited by (772)

Items 701–772 of 772

1. Depression and non-alcoholic fatty liver disease: Association and potential mechanisms
   Hai-Ling Peng, Li‐Ni Liu, Deliang Liu, Yuyong Tan · 2022 · World Chinese Journal of Digestology
2. Pleyotropic Effects of Statins Non-Alcoholic Fat Disease of the Liver Non-Alcoholic Steatohepatitis
   И.Р. Агабабян, Ш. С. Садыкова · 2022 · Рецепт
3. Faculty Opinions recommendation of The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis.
   Joel E. Lavine · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
4. Faculty Opinions recommendation of Sexual Dimorphism of NAFLD in Adults. Focus on Clinical Aspects and Implications for Practice and Translational Research.
   Stefano Bellentani, Natalia Rosso · 2020 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
5. Professional standards launched for bariatric care
   2013 · British Journal of Hospital Medicine
6. New nasal spray for the treatment of moderate to severe allergic rhinitis
   2013 · British Journal of Hospital Medicine
7. Cardiovascular issues increase mortality rates in patients with advanced fibrosis
   2013 · British Journal of Hospital Medicine
8. Surgery for endometriosis lowers risk of ovarian cancer
   2013 · British Journal of Hospital Medicine
9. Journal of Liver
   2019
10. Prognostic non-invasive biomarkers for all-cause mortality in non-alcoholic fatty liver disease: A systematic review and meta-analysis
    Nicole Cianci, Mohsan Subhani, Trevor Hill, Amardeep Khanna, Dong Zheng, Abhishek Sheth, Colin John Crooks, Guruprasad Padur Aithal · 2022 · World Journal of Hepatology
11. Doença hepática gordurosa não alcoólica (DHGNA) e síndrome dos ovários policísticos (SOP): associação do polimorfismo no gene da patatin-like phospholipase domain containing 3 (PNPLA3) e alterações endócrinas e metabólicas
    Amanda Medeiros Recuero · 2022 · Digital Library of Theses and Dissertations (Universidade de São Paulo)
12. Reply
    Donghee Kim, Peter Konyn, Aijaz Ahmed · 2022 · Clinical Gastroenterology and Hepatology
13. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: new trends and role of ultrasonography
    Toshifumi Tada, Takashi Nishimura, Masahiro Yoshida, Hiroko Iijima · 2022 · Choonpa Igaku
14. Natürlicher Verlauf
    Münevver Demir, Hans‐Michael Steffen · 2022 · Springer eBooks
15. Prevalence, Trends, and Characteristics of Nonalcoholic Fatty Liver Disease among the US Population Aged 12–79 Years
    Tsung‐Hua Shen, Chung‐Hsuen Wu, Yuan‐Wen Lee, Chun‐Chao Chang · 2022 · Research Square
16. Relationship of Midkine in Myocardial Infarction patients and some biochemical parameters
    Obeda Abdlkhaliq Abass Alkado, Luay A. Al-Helaly · 2022 · Journal of Contemporary Medical Sciences
17. Prognostic Value Of Coronary Artery Calcium Score For The Prediction Of Cardiovascular Disease In Participants With Nonalcoholic Fatty Liver Disease: Results From The Multi-ethnic Study Of Atherosclerosis
    Keishi Ichikawa, S. Hansen, V. Manubolu, Leili Pourafkari, Hooman Fazlalizadeh, Jairo Aldana-Bitar, Lisa B. VanWagner, Srikanth Krishnan, Matthew Jay Budoff · 2023 · Journal of cardiovascular computed tomography
18. Liver fibrosis assessed using non-invasive markers and genetic polymorphisms ( PNPLA3 and TM6SF2 ) predisposing to liver fibrosis, is associated with hospitalization or death from heart failure: a prospective UK Biobank study
    Theresa Hydes, Oliver John Kennedy, Kate Glyn‐Owen, Ryan Malcolm Buchanan, Julie Parkes, Daniel James Cuthbertson, Paul J. Roderick, Christopher D. Byrne · 2023 · medRxiv
19. Association of Liver Fibrosis Risk Scores with Cardiovascular and All-Cause Mortality in Us General Population: Results from Nhanes 1999–2014
    Yue Yu, Kaiyan Chen, Yan Hua, Gaoyuan Ge, Wei Zhao, Dan Bo, Rui Zhu, Tianyu Wu, Qiushi Chen, Fengxiang Zhang · 2023 · SSRN Electronic Journal
20. Additional file 1 of Effects of glucagon-like peptide-1 receptor agonists on liver-related and cardiovascular mortality in patients with type 2 diabetes
    Fu‐Shun Yen, Ming‐Chih Hou, James Cheng‐Chung Wei, Ying‐Hsiu Shih, Chii‐Min Hwu, Chih‐Cheng Hsu · 2024 · Figshare
21. Lean non-alcoholic fatty liver disease is associated with increased all-cause mortality in the United States
    Yutong Wu, Lili Wang, Jiayi Yi, Xiangpeng Ren · 2024 · Research Square
22. Povara bolii ficatului steatozic
    Felicia Darii, Olga Tagadiuc · 2024 · Akademos
23. Alterations in the Expression of Proteins Associated with Non-Alcoholic Fatty Liver Disease Observed in the Liver of the C57Bl/6 Wild-Type Male Mouse in Response to Exposure of Mixed Vehicle Emissions and/or High Fat Diet Consumption
    Leah Jayne Schneider · 2022 · University of North Texas Digital Library (University of North Texas)
24. Combination of fibrosis-4 score and D-dimer: a practical approach to identify poor outcome in COVID-19
    Fernanda Manhães Pozzobon, Ronir Raggio Luiz, Júlia Gomes Parente, Taísa Melo Guarilha, Maria Paula Raymundo Cunha Fontes, Maria Chiara Chindamo, Renata de Mello Perez · 2025 · European Journal of Gastroenterology & Hepatology
25. The cross-sectional study on changes in fasting lipid profile and liver enzyme in type 2 diabetic patients in tertiary healthcare
    Paras Desai, Sanket Rathod, Harshil Bhavsar, Bhavik Prajapati, Sachin Patel, Mehul Kaliya · 2025 · International Journal of Research in Medical Sciences
26. Association of Antihypertensive Medication and Steatotic Liver Disease with Liver Fibrosis and Mortality among US Adults
    Yu Wu, Fei Fang · 2025 · medRxiv
27. Controversias en la nomenclatura: de la esteatohepatitis no alcohólica al espectro completo de la esteatosis hepática
    Manuel Romero‐Gómez, Sebastian Eduardo Ferretti, Juan Pablo Arab · 2025 · Medicina Clínica
28. Low Hepatic CEACAM1 Tethers Metabolic Dysfunction Steatohepatitis to Atherosclerosis
    Sacha El Khoury, Sami N. Al Harake, Tya Youssef, Carl E. Risk, Nabil Helou, Natalie M. Doumet, Karl Aramouni, Sami T. Azar, Sonia Michael Najjar, Hilda E. Ghadieh · 2025 · Livers
29. Assessment of the risk of developing cefepime-induced abnormal liver enzyme levels using the albumin–bilirubin score and fibrosis-4 index: a single-centre retrospective case–control study
    Hiroki Katsu, Yuki Asai, Takuya Iwamoto, Ryuji Hirano · 2025 · Journal of Antimicrobial Chemotherapy
30. Controversies in nomenclature: From nonalcoholic steatohepatitis to the full spectrum of hepatic steatosis
    Manuel Romero‐Gómez, Sebastian Eduardo Ferretti, Juan Pablo Arab · 2025 · Medicina Clínica (English Edition)
31. Coffee and Metabolic Syndrome/MAFLD
    Arrigo F.G. Cicero, Federica Fogacci, Valentina Di Micoli · 2025 · Springer eBooks
32. Investigating the Effect of Royal Jelly Supplementation on Improvement of Glucose Profile, Lipid Profile, Liver Factors, Inflammation and Anthropometric Indices in Patients with Non-alcoholic Fatty Liver Disease in the Nutrition Clinic of the Islamic Azad University and Shahid Beheshti Medical Sciences Hospital Centers in 1402, a Randomized, Double-Blind Clinical Trial
    F hasannia, Seyed Ali Keshavarz, Mahdi Shadnoush · 2025 · Journal of Nutrition Sciences and Food Technology
33. Features of the development and treatment of lipid metabolism disorders in patients with metabolic dysfunction-associated steatotic liver disease: A review
    Dmitry I. Darenskiy · 2025 · Consilium Medicum
34. Additional file 1 of The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease
    Paul M. Trembling, Sophia Apostolidou, A Gentry-Maharaj, Julie Parkes, Andy Ryan, Sudeep Tanwar, Matthew Burnell, Harris, Scott, Usha Menon, William M. Rosenberg · 2020 · Figshare
35. Additional file 1 of Economic burden of non-alcoholic steatohepatitis with significant fibrosis in Thailand
    Pochamana Phisalprapa, Ratthanon Prasitwarachot, Chayanis Kositamongkol, Pranaidej Hengswat, Weerachai Srivanichakorn, Chaiwat Washirasaksiri, Treeprasertsuk, Sombat, Phunchai Charatcharoenwitthaya, Nathorn Chaiyakunapruk · 2021 · Figshare
36. Additional file 4 of Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients
    Liu, Yupeng, Song, Jingjing, Wang, Wenyao, Kuo Zhang, Yang, Jie, Wen, Jun, Xiangbin Meng, Gao, Jun, Jingjia Wang, Chunli Shao et al. · 2023 · Figshare
37. Additional file 6 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
38. Additional file 10 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
39. Additional file 12 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
40. Additional file 3 of Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients
    Liu, Yupeng, Song, Jingjing, Wang, Wenyao, Zhang, Kuo, Yang, Jie, Wen, Jun, Xiangbin Meng, Gao, Jun, Jingjia Wang, Chunli Shao et al. · 2023 · Figshare
41. Additional file 7 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
42. Additional file 1 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
43. Additional file 1 of Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients
    Liu, Yupeng, Song, Jingjing, Wang, Wenyao, Kuo Zhang, Yang, Jie, Wen, Jun, Xiangbin Meng, Gao, Jun, Jingjia Wang, Chunli Shao et al. · 2023 · Figshare
44. Additional file 3 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
45. Additional file 4 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
46. Additional file 5 of Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients
    Liu, Yupeng, Song, Jingjing, Wang, Wenyao, Zhang, Kuo, Yang, Jie, Wen, Jun, Xiangbin Meng, Gao, Jun, Jingjia Wang, Chunli Shao et al. · 2023 · Figshare
47. Additional file 8 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
48. Additional file 2 of Association between liver fibrosis and thrombotic or bleeding events in acute coronary syndrome patients
    Liu, Yupeng, Song, Jingjing, Wang, Wenyao, Kuo Zhang, Yang, Jie, Wen, Jun, Xiangbin Meng, Gao, Jun, Jingjia Wang, Chunli Shao et al. · 2023 · Figshare
49. Additional file 9 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
50. Additional file 5 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
51. Additional file 2 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
52. Additional file 13 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
53. Additional file 11 of The impact of non-alcoholic fatty liver disease and liver fibrosis on adverse clinical outcomes and mortality in patients with chronic kidney disease: a prospective cohort study using the UK Biobank
    Theresa Hydes, Oliver John Kennedy, Buchanan, Ryan, Cuthbertson, Daniel J., Julie Parkes, Fraser, Simon D. S., Roderick, Paul · 2023 · Figshare
54. Neither Metabolic Dysfunction Associated Steatotic Liver Disease Presence Nor Fibrosis Severity, By FIB4, Predicts Adverse Pregnancy Outcomes
    Christine Lopez, Zoe R. Finer, Suzanne R. Sharpton, Rolanda Lister, Jennifer L. Thompson, Christopher John Lindsell, Yue Gao, HILLARY E. DUCKHAM, Manhal J. Izzy · 2026 · Journal of Clinical Gastroenterology
55. Association of FIB-4 with orthostatic hypotension in Parkinson's disease
    Wen Zhou, Tianfang Zeng, Duan Liu, Ruijuan Pang, Liang Gong · 2026 · Autonomic Neuroscience
56. Corrigendum. Multidisciplinary clinical practice guideline on the management of metabolic hepatic steatosis
    Manuel Romero-Gómez, Javier Escalada, Mar Noguerol, Antonio Pérez, Juana Carretero, Javier Crespo, Juan J Mascort, Ignacio Aguilar, Francisco Tinahones, Pedro Cañones et al. · 2026 · Gastroenterología y Hepatología (English Edition)
57. Cardiovascular Risk in Patients With and Without Metabolic Dysfunction-Associated Steatotic Liver Disease: A Clinical and Subclinical Evaluation (Preprint)
    Mohamed Yousef Abdallah Yousef Omar · 2026
58. Safety of Statins in an Asian Cohort with Biopsy Proven Metabolic Dysfunction-Associated Steatotic Liver Disease
    Wei Lun Liou, Yiying Pei, Kevin Kim‐Jun Teh, Mark Chang Chuen Cheah, Wei Qiang Leow, Tony Kiat‐Hon Lim, George Boon‐Bee Goh · 2026 · Digestive Diseases and Sciences
59. Marqueurs non-invasifs de stéatose et fibrose hépatique
    Hugo Perazzo · 2014 · theses.fr (ABES)
60. Performances pronostiques du FibroTest chez les sujets avec maladie métabolique du foie
    Mona Munteanu · 2018
61. Rôle du récepteur nucléaire CAR dans la pathogénèse dimorphique de la NAFLD (Non-Alcoholic Fatty Liver Disease), induite par un régime gras ou par l'exposition à des contaminants alimentaires
    Fabiana Oliviero · 2021 · theses.fr (ABES)
62. Effect of nonalcoholic fatty liver disease on post-myocardial infarction cardiac remodeling
    Louise Biquard · 2022 · theses.fr (ABES)
63. Can the FIB-4 index predict mortality in patients with coronary artery disease? A systematic review and meta-analysis
    Robert Willian Anastácio Alcântara, Vinícius Martins Rodrigues Oliveira, Nathalia Schettino Samad, Lucas Barbosa, Weimar Kunz Sebba Barroso, Wilson Nadruz, Raul Cavalcante Maranhão, Bruno Ramos Nascimento, Ignacio Jesus Amat-Santos, Humberto Graner Moreira · 2026 · Current Problems in Cardiology
64. Ageing liver in the era of MASLD: risks, mechanisms and treatment opportunities
    Saleh A. Alqahtani, Carolin Victoria Schneider, Jörn Markus Schattenberg · 2026 · Frontline Gastroenterology
65. Fibrotic NASH Index ( FNI ) Is Associated with Long‐Term Mortality in Individuals with Type 2 Diabetes and MASLD
    Ilaria Barchetta, Flavia Agata Cimini, Sara Dule, Giulia Passarella, Alessandro Oldani, Maria Neve Hirsch, Marta Cirelli, Marta Alfano, Maria Gisella Cavallo · 2026 · Liver International
66. Transcriptomic and Proteomic Analyses Identify THBS2, VWF, NFASC, and AKR1B10 as Diagnostic Biomarkers for Advanced Fibrosis in NAFLD
    Shan Ding, Yiqing Liu, Zhi Liu, Fulu Chu, Bingru Lu, Li Xu · 2026 · Journal of Inflammation Research
67. Does Fetuin-A, RAGE, FGF-23 levels associated with cardiovascular risk or fibrosis score in patients with metabolic dysfunction-associated steatotic liver disease?
    Zeynep Tuğba Ozan, Ayşe Yeşim Göçmen, Mehmet Çelikbilek, Tekin Yıldırım · 2026 · Anatolian Current Medical Journal
68. Cardiovascular Risk in Patients With and Without Metabolic Dysfunction-Associated Steatotic Liver Disease: A Clinical and Subclinical Evaluation (Preprint)
    Mohamed Yousef Abdallah Yousef Omar · 2026
69. Cardiovascular disease risk in patients with and without metabolic dysfunction-associated steatotic liver disease: A clinical and subclinical evaluation
    A.Y. Omar Mohamed Yousef, Amany Mansour E. El-mallah, Mohamed Gamal M. A. Bakr, Mohamed Mahmoud E. Ragab · 2026 · American Heart Journal Plus Cardiology Research and Practice
70. Metabolic dysfunction-associated fatty liver disease increases the risk of new-onset type 2 diabetes mellitus: a retrospective cohort study based on health check-up data
    Lihua Sun, Feng Chen, Jing Li · 2026 · Frontiers in Medicine
71. Predictive Value of Gamma Glutamyl Transferase Platelet Ratio in The Development of Liver Fibrosis and Steatohepatitis in Chronic Hepatitis B Patients
    Mine Büşra Bozkürk, Yusuf Coşkun, Gülnur Kul, Funda GÜÇEL, Ramazan Berk Us, Merve Tura Çelik, Alpaslan Öztürk, Emin Ediz Tütüncü · 2026 · Online Türk Sağlık Bilimleri Dergisi
72. The MASLD–Heart Axis: Biological Mechanisms, Cardiac Remodeling, and Clinical Implications
    Evangelos K. Oikonomou, Nikolaos P. Machairas, Panagiotis Theofilis, Anna Maria Louka, Maria Xenou, Panagiota K. Stampouloglou, Ουρανία Κατσαρού, Nikolaos K. Kokkinos, Antonios Lysandrou, Stergios Karamesinis-Spinthakis et al. · 2026 · Pharmaceuticals